FDA approves new drug for specific type of advanced breast cancer.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D017277:Drug Approval; D066246:ErbB Receptors; D005260:Female; D006801:Humans; D000077341:Lapatinib; D011799:Quinazolines / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077341:Lapatinib; D066246:ErbB Receptors